Tevogen Bio (TVGN) Projected to Announce Quarterly Earnings on Friday

Tevogen Bio (NASDAQ:TVGN) is expected to release its results before the market opens on Friday, November 13th. Analysts expect the company to post earnings of ($2.5550) per share for the quarter.

Tevogen Bio (NASDAQ:TVGN) last issued its quarterly earnings results on Friday, August 14th. The company reported ($1.52) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.53) by $1.01.

Tevogen Bio Stock Performance

Shares of TVGN opened at $5.66 on Thursday. Tevogen Bio has a one year low of $3.64 and a one year high of $24.91. The stock has a market capitalization of $36.82 million, a price-to-earnings ratio of -1.22 and a beta of 0.21. The stock has a 50 day moving average price of $6.80 and a 200 day moving average price of $7.84.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Tevogen Bio in a research note on Thursday, October 15th. One research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Tevogen Bio currently has a consensus rating of “Reduce” and a consensus target price of $100.00.

Tevogen Bio Company Profile

Tevogen Bio is a clinical-stage biotechnology company focused on developing off-the-shelf T-cell therapies for patients with viral infections, cancer and other serious medical conditions. Its approach is designed to use virus-specific cytotoxic T lymphocytes to target diseased cells while limiting the challenges associated with individualized cell therapies. The company’s lead program, TVGN 489, is an investigational T-cell therapy intended to address COVID-19 and other conditions caused by SARS-CoV-2, particularly among immunocompromised patients.